RxDoctor Payments Data

Toan Tran, MD

Internal Medicine · Milpitas, CANPI 1588683031

Payments from drug & device makers

$1,440in general payments, 2019–2025

Across 32 payments — averaging $45.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$316
  • Gilead$257
  • Johnson & Johnson$178
  • Amarin Pharma, Inc.$152
  • Novo Nordisk$125
  • Novartis$122
  • plus $291 from 5 others

What the payments were for

  • Food & beverage$1,41198%
  • Education$302%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,440 in reported general payments places this provider in the 75th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$71,378
Medicare patients
141
Services billed
585

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin273$294,028
OzempicSemaglutide38$57,917
TradjentaLinagliptin44$45,357
RybelsusSemaglutide33$42,816
FarxigaDapagliflozin Propanediol44$36,107
TrulicityDulaglutide24$29,948
JanuviaSitagliptin Phosphate30$28,898
MounjaroTirzepatide27$27,536
CreonLipase/Protease/Amylase16$25,558
EliquisApixaban33$25,244
VascepaIcosapent Ethyl29$14,485
Icosapent Ethyl28$10,940
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$10,018
Atorvastatin Calcium1,005$9,984
LinzessLinaclotide15$8,566

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$316$339,385317 claims
Novo NordiskOzempic, Rybelsus$125$100,73471 claims
Scilex Pharmaceuticals Inc.Colchicine$61$1,49737 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Milpitas

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →